FibroBiologics’ (FBLG) Hold Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their hold rating on shares of FibroBiologics (NASDAQ:FBLG) in a research report released on Thursday, MarketBeat reports.

A number of other research analysts also recently issued reports on FBLG. Weiss Ratings reiterated a “sell (e+)” rating on shares of FibroBiologics in a report on Thursday, January 22nd. HC Wainwright cut their target price on FibroBiologics to $80.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, FibroBiologics currently has a consensus rating of “Hold” and a consensus target price of $110.00.

FibroBiologics Stock Down 10.6%

Shares of NASDAQ:FBLG opened at $0.20 on Thursday. The firm has a market cap of $13.81 million, a price-to-earnings ratio of -0.47 and a beta of -0.69. FibroBiologics has a 12 month low of $0.19 and a 12 month high of $1.53. The company’s fifty day simple moving average is $6.02 and its 200 day simple moving average is $7.00.

Shares of FibroBiologics are going to reverse split on the morning of Monday, March 30th. The 1-20 reverse split was announced on Wednesday, March 25th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, March 27th.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.80) by $1.20. Research analysts expect that FibroBiologics will post -0.53 earnings per share for the current fiscal year.

Insider Buying and Selling

In other FibroBiologics news, CFO Jason Davis acquired 3,500 shares of FibroBiologics stock in a transaction dated Monday, March 2nd. The stock was bought at an average cost of $8.20 per share, for a total transaction of $28,700.00. Following the purchase, the chief financial officer directly owned 3,500 shares in the company, valued at approximately $28,700. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders have bought 9,574 shares of company stock worth $72,886. Insiders own 13.00% of the company’s stock.

Institutional Trading of FibroBiologics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Yorkville Advisors Global LP bought a new stake in FibroBiologics during the third quarter worth about $278,000. Landscape Capital Management L.L.C. acquired a new position in FibroBiologics during the third quarter valued at approximately $191,000. Cerity Partners LLC grew its stake in FibroBiologics by 37.2% in the second quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock valued at $80,000 after purchasing an additional 34,702 shares in the last quarter. Geode Capital Management LLC increased its position in shares of FibroBiologics by 20.7% during the 4th quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock worth $78,000 after purchasing an additional 59,813 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of FibroBiologics during the 2nd quarter worth approximately $60,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.